Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jan 8;30(3):424–430. doi: 10.1093/annonc/mdy550

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 1. — Alternate promoter utilization in gastric cancer (pembrolizumab trial cohort, n = 37). (A) Heatmap of alternate promoter utilization. Transcript with higher than fourfold expression level compared with the median level in all tumor and mapping to the previously identified gain alternative promoter site were considered as gained alternative promoter (marked red in the heatmap). Transcript with lower than fourfold expression level compared with the median level in all tumor and mapping to the previously identified lost alternative promoter site were considered as lost alternative promoter (marked blue in the heatmap). (B) Alternative promoter utilization score is calculated as the sum of gained and lost alternative promoter in each sample. High alternate promoter utilization was defined as those >66th centile. (C) Association between high alternate promoter (AP_high) group and low alternate promoter (AP_low) group with T-cell immune correlates. AP_high group are in red, whereas those in AP_low group are in blue. Depicted are the expression of T-cell markers CD8A (P = 0.0037) and the T-cell cytolytic markers GZMA (P = 0.0055) and PRF1 (P = 0. 016). AP_high group shows lower expression of immune markers. (D) Waterfall plot of response to pembrolizumab according to AP_high (red) and AP_low (blue) subgroups. Y axis represents percentage of maximum tumor reduction assessed according to RECIST 1.1 criteria.